Loading...

APC anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_APC_090507
C57BL/6 mouse splenocytes stained with 30-F11 APC
  • 30-F11_APC_090507
    C57BL/6 mouse splenocytes stained with 30-F11 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
103111 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103112 100 µg 76€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Jiang Z, et al. 2021. J Clin Invest. 131: . PubMed
  2. Garo LP, et al. 2021. Nat Commun. 12:2419. PubMed
  3. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  4. Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed
  5. Nigam S, et al. 2020. Mol Imaging Biol. 22:685. PubMed
  6. Yang D, et al. 2022. Cell. 185:1905. PubMed
  7. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  8. Gavin KM, et al. 2018. Front Endocrinol (Lausanne). 9:276. PubMed
  9. Wang L, et al. 2018. Bone Res. 6:22. PubMed
  10. Cha JH et al. 2018. Molecular cell. 71(4):606-620 . PubMed
  11. Haimon Z et al. 2018. Nature immunology. 19(6):636-644 . PubMed
  12. Ying W, et al. 2019. Cell Metab. 29:457. PubMed
  13. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  14. Mourao L, et al. 2019. Sci Rep. 0.991666667. PubMed
  15. Oetjen LK et al. 2017. Cell. 171(1):217-228 . PubMed
  16. Testini C, et al. 2019. EMBO Rep. 20:e47845. PubMed
  17. Gao Q, et al. 2019. J Exp Med. 216:688. PubMed
  18. Shavit Stein E, et al. 2018. Neural Plast. 2018:7692182. PubMed
  19. Bouchareychas L, et al. 2021. iScience. 24(8):102847. PubMed
  20. Almada AE, et al. 2021. Cell Reports. 34(4):108656. PubMed
  21. Kim JS, et al. 2020. Immunity. 54(1):176-190.e7. PubMed
  22. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  23. Jaiswal AK, et al. 2020. Immunobiology. 225:151956. PubMed
  24. Cayre S, et al. 2020. Development. 147:00:00. PubMed
  25. Díaz NM, et al. 2020. Invest Ophthalmol Vis Sci. 61:37:00. PubMed
  26. Rosa FF, et al. 2020. Bio Protoc. 10:e3619. PubMed
  27. Wang Y, et al. 2021. J Bone Oncol. 30:100386. PubMed
  28. Lu L, et al. 2022. Sci Rep. 12:931. PubMed
  29. Parhiz H, et al. 2022. J Control Release. 344:50. PubMed
  30. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  31. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  32. Kang I, et al. 2012. Blood. 119:3295. PubMed
  33. Ahmed M, et al. 2016. Development. 143: 1663 - 1673. PubMed
  34. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  35. Lim JT, et al. 2020. Mol Cancer Ther. 1809:19. PubMed
  36. Chen J, et al. 2022. Nat Commun. 13:6759. PubMed
  37. Wang S, et al. 2022. Front Immunol. 13:869061. PubMed
  38. Zhang Y, et al. 2022. Cancers (Basel). 14:. PubMed
  39. Barwe SP, et al. 2022. J Clin Med. 11:. PubMed
  40. Tilstam PV, et al. 2021. J Clin Invest. 131:. PubMed
  41. Yu X, et al. 2021. Nature. 594:560. PubMed
  42. Sato S, et al. 2021. Int J Mol Sci. 22:. PubMed
  43. Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed
  44. Engelbrecht E, et al. 2020. eLife. 9:e52690.. PubMed
  45. Hays C, et al. 2020. eLife. 8:e48772.. PubMed
  46. Lechner AJ et al. 2017. Cell stem cell. 21(1):120-134 . PubMed
  47. Yanagida K, et al. 2020. Dev Cell. 779:52. PubMed
  48. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  49. Larouche JA, et al. 2021. eLife. 0.416666666666667. PubMed
  50. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  51. Barberio AE, et al. 2020. ACS Nano. 14:11238. PubMed
  52. Chiche A, et al. 2016. Oncogene. 10.1038/onc.2016.396. PubMed
  53. Eastman A, et al. 2016. J Immunol . 194: 5999-6010. PubMed
  54. Park JA, et al. 2021. J Hematol Oncol. 14:142. PubMed
  55. Romagnoli M, et al. 2020. Development. 147:. PubMed
  56. Li Q, et al. 2021. Brain Behav Immun. 94:437. PubMed
  57. Wang X, et al. 2022. Nat Aging. 2:155. PubMed
  58. Wang T, et al. 2020. Blood Sci. 2:79. PubMed
  59. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  60. Duarte N, et al. 2018. Hepatol Commun. 0.833333333. PubMed
  61. Strunz M, et al. 2020. Nat Commun. 2.929861111. PubMed
  62. Shemer A, et al. 2020. Immunity. 53(5):1033-1049.e7. PubMed
  63. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  64. Wosczyna MN, et al. 2021. Cell Stem Cell. 28(7):1323-1334.e8. PubMed
  65. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  66. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  67. Motoyama S, et al. 2020. Cells. :9. PubMed
  68. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  69. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  70. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  71. Bourn JR, et al. 2021. Cancer Lett. 503:75. PubMed
  72. Khateb M, et al. 2022. Cell Rep. 40:111219. PubMed
  73. Xu Q, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  74. Liu K, et al. 2022. Theranostics. 12:639. PubMed
  75. Sato Y, et al. 2021. J Clin Invest. Online ahead of print. PubMed
  76. Pelletier A, et al. 2012. J Immunol. 188:5561. PubMed
  77. Herting CJ, et al. 2019. Brain. 142:3834. PubMed
  78. Romagnoli M, et al. 2019. Stem Cell Reports. 1.077083333. PubMed
  79. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  80. De S, et al. 2018. Development. 145. PubMed
  81. Xiao X, et al. 2019. Cell Discov. 5:2. PubMed
  82. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  83. Amouyal C, et al. 2020. EBioMedicine. 58:102895. PubMed
  84. Liu L, et al. 2015. Neurol Neuroimmunol Neuroinflamm. 2: 174. PubMed
  85. Hyatt L, et al. 2014. PLoS One. 9:109072. PubMed
  86. Hu EY, et al. 2021. Blood Adv. 5:3152. PubMed
  87. Palathingal Bava E, et al. 2022. JCI Insight. 7:. PubMed
  88. An J,et al. 2017. Sci Rep.. 10.1038/s41598-017-13629-0. PubMed
  89. Wosczyna MN et al. 2019. Cell Rep. 27(7):2029-2035 . PubMed
  90. Maston LD, et al. 2017. Am J Physiol Lung Cell Mol Physiol. 312:L609. PubMed
  91. Bresson L, et al. 2018. Development. 145. PubMed
  92. Charmsaz S, et al. 2017. Leukemia. 31:1779. PubMed
  93. Sambasivan R, et al. 2011. Development. 138:3647. PubMed
  94. Lafkas D, et al. 2013. J Cell Biol. 203:47. PubMed
  95. Ma S, et al. 2021. Cell Reports. 34(6):108726. PubMed
  96. Ankawa R, et al. 2021. Developmental Cell. . PubMed
  97. Fischer A, et al. 2022. Nat Immunol. 23:518. PubMed
  98. Hu J, et al. 2022. Cell Mol Neurobiol. . PubMed
  99. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  100. Kotfis K, et al. 2020. British Journal of Pharmacology. 49(1):66-72. PubMed
  101. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  102. Varol D et al. 2017. Immunity. 46(6):1030-1044 . PubMed
  103. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  104. Zheng B, et al. 2018. J Hematol Oncol. 11:16. PubMed
  105. Pal B, et al. 2017. Nat Commun.. 10.1038/s41467-017-01560-x. PubMed
  106. Shcherbina A, et al. 2020. Cell Rep. 32:107964. PubMed
  107. Wu J, et al. 2020. Immunity. 53:115. PubMed
  108. Frii J, et al. 2021. Immunity. 54(5):1002-1021.e10. PubMed
  109. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  110. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  111. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  112. Thinard R, et al. 2022. Pharmaceutics. 14:. PubMed
  113. Yang H, et al. 2022. Nutrients. 14:. PubMed
  114. Hu J, et al. 2022. J Neuroinflammation. 19:71. PubMed
  115. Pezoldt J, et al. 2022. Nat Commun. 13:7227. PubMed
  116. Yuan Z, et al. 2018. Emerg Microbes Infect. 7:59. PubMed
  117. Hou M, et al. 2020. Stem Cell Res Ther. 11:55. PubMed
  118. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  119. Crooks SD, et al. 2022. Immunohorizons. 6:705. PubMed
  120. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  121. Harnett MM, et al. 2022. Front Immunol. 13:953053. PubMed
  122. Koren E, et al. 2022. Nat Commun. 13:4628. PubMed
  123. Bauer T, et al. 2021. Life (Basel). 11:. PubMed
  124. Li P, et al. 2022. EMBO Mol Med. 14:e14511. PubMed
  125. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  126. Myerson JW, et al. 2021. Nat Nanotechnol. Online ahead of print. PubMed
  127. Dudek KA, et al. 2020. Proc Natl Acad Sci U S A. 117:3326. PubMed
  128. Bradley KC, et al. 2019. Cell Rep. 28:245. PubMed
  129. Jia Q, et al. 2021. Theranostics. 4699:11. PubMed
  130. Paiva-Oliveira E, et al. 2017. Histochem Cell Biol. 10.1007/s00418-017-1556-6. PubMed
  131. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  132. Yang Y, et al. 2022. Elife. 11:. PubMed
  133. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  134. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  135. Scur M, et al. 2022. Nat Commun. 13:7272. PubMed
  136. Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed
  137. Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed
  138. Zhou G, et al. 2019. FASEB J. 33:11396. PubMed
  139. Wang C, et al. 2011. Hepatology. 55:108. PubMed
  140. Sim S, et al. 2016. PLoS One. 11: 0152485. PubMed
  141. Mangum L, et al. 2016. Toxicol Sci. 150: 169 - 177. PubMed
  142. Mizuno T, et al. 2017. Sci Rep. 7:42714. PubMed
  143. Nosho S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  144. Engler AE, et al. 2020. Cell Reports. 33(13):108553. PubMed
  145. Limbad C, et al. 2022. iScience. 25:103848. PubMed
  146. Chiang HY, et al. 2022. Nat Commun. 13:874. PubMed
  147. Aguilera M, et al. 2021. Int J Mol Sci. 22:. PubMed
  148. Yamada KJ, et al. 2020. PLoS Pathog. 16:e1008354. PubMed
  149. Tu WL, et al. 2018. Am J Pathol. 188:2688. PubMed
  150. Chiche A, et al. 2019. Breast Cancer Res. 21:13. PubMed
  151. Feng J,et al. 2017. Nat Commun. . 10.1038/s41467-017-01056-8. PubMed
  152. Xi W, et al. 2021. Stem Cell Res Ther. 167:12. PubMed
  153. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  154. Dawson CA, et al. 2021. Nature Protocols. 16(4):1907-1935. PubMed
  155. Seki T, et al. 2015. J Biochem. 158: 485 - 495. PubMed
  156. Dion-Albert L, et al. 2022. Nat Commun. 13:164. PubMed
  157. Long JT, et al. 2022. Elife. 11:. PubMed
  158. Zhang Z, et al. 2021. Exp Dermatol. 30:102. PubMed
  159. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  160. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  161. Shi R, et al. 2019. J Cancer. 10:367. PubMed
  162. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  163. Usmani SM et al. 2019. Cell host & microbe. 25(1):73-86 . PubMed
  164. Zasłona Z, et al. 2017. Am J Physiol Lung Cell Mol Physiol. 312:L855. PubMed
  165. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  166. Liu D, et al. 2020. Front Pharmacol. 11:204. PubMed
  167. Garcia-Bonilla L, et al. 2014. J Immunol. 193:2531. PubMed
  168. Ding X, et al. 2015. J Immunol. 194:4251. PubMed
  169. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  170. Mueller A, et al. 2016. Nature. 540:276-279. PubMed
  171. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  172. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  173. Penkert RR, et al. 2020. Obesity (Silver Spring). 1631:28. PubMed
  174. Mori A, et al. 2021. Cells. :10. PubMed
  175. Saber M, et al. 2021. J Neurosci Res. 99:1136. PubMed
  176. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  177. Murdock BJ, et al. 2021. JCI Insight. 6:. PubMed
  178. Cai B, et al. 2020. Cell Metabolism. 31(2):406-421.e7.. PubMed
  179. Lu Y, et al. 2020. Immunity. 52:782. PubMed
  180. Toyama K, et al. 2018. Arterioscler Thromb Vasc Biol. 38:1392. PubMed
  181. Qiao S, et al. 2019. J Neuroinflammation. 16:4. PubMed
  182. Yang Y, et al. 2021. Cell Reports. 34(10):108822. PubMed
  183. Taya M, et al. 2020. Endocr Relat Cancer. 27:261. PubMed
  184. Zhang J, et al. 2022. Biomater Res. 26:44. PubMed
  185. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  186. Carmody C et al. 2019. Endocrinology. 160(5):1205-1222 . PubMed
  187. Fu NY, et al. 2018. Dev Cell. 47:629. PubMed
  188. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
  189. Yeo SK, et al. 2020. eLife. 9:e58810.. PubMed
  190. Elias S, et al. 2015. PLoS Biol. 13:1002142. PubMed
  191. Deng P, et al. 2021. Cell Stem Cell. 28(6):1057-1073.e7. PubMed
  192. Zhang Y, et al. 2020. Cancer Res. 80:3345. PubMed
  193. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  194. Nasser H, et al. 2020. Cell Death Discov. 0.29375. PubMed
  195. Sroor HM, et al. 2019. Sci Rep. 9:20217. PubMed
  196. Chen PY, et al. 2019. Nat Metab. 0.675. PubMed
  197. Cao Y, et al. 2019. Nat Commun. 10:1280. PubMed
  198. Liu L et al. 2018. Cell stem cell. 23(4):544-556 . PubMed
  199. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  200. Cai T, et al. 2022. Nat Commun. 13:2228. PubMed
  201. Kim KS, et al. 2022. JCI Insight. 7:. PubMed
  202. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  203. Zhang T, et al. 2020. JCI Insight. 5:00. PubMed
  204. Gopalakrishnapillai A, et al. 2021. Cancers (Basel). 13:. PubMed
  205. Liu G, et al. 2022. Theranostics. 12:2248. PubMed
  206. Piirainen S, et al. 2021. Glia. 69:2459. PubMed
  207. Arora S, et al. 2021. Med (N Y). 2:938. PubMed
  208. Li H, et al. 2022. iScience. 25:104481. PubMed
  209. Cayre S, et al. 2020. Development. . PubMed
  210. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  211. Pal B, et al. 2021. Breast Cancer Res. 23:69. PubMed
  212. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  213. Ortiz A, et al. 2019. Cancer Cell. 35:33:00. PubMed
  214. Ouadah Y, et al. 2019. Cell. 179:403. PubMed
  215. Piotrowski AF, et al. 2018. Oncoimmunology. 7:e1445951. PubMed
  216. Sarshad AA, et al. 2018. Mol Cell. 71:1040. PubMed
  217. Saber M, et al. 2020. Eur J Neurosci. 52:2791. PubMed
  218. Vaas M, et al. 2016. J Cereb Blood Flow Metab. 10.1177/0271678X16676825. PubMed
  219. Wong J, et al. 2016. Sci Signal. 9: ra103. PubMed
  220. Yuan Z, et al. 2016. J Virol. 90: 7728 - 7739. PubMed
  221. Garcia-Bonilla L, et al. 2015. J Neurosci. 35: 14783 - 14793. PubMed
  222. Jiang Y, et al. 2015. MBio. 6: e01426-15. PubMed
  223. Roberts L, et al. 2014. Infect Immun . 82:2504. PubMed
  224. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  225. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  226. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  227. Wunderlich CM, et al. 2018. Nat Commun. 9:1646. PubMed
  228. Peltzer N, et al. 2018. Nature. 557:112. PubMed
  229. Qu Y, et al. 2020. Cell Reports. 32(1):107873. PubMed
  230. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  231. Koh BI, et al. 2020. Nat Commun. 3.143055556. PubMed
  232. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  233. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  234. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  235. Liu C, et al. 2022. Nat Commun. 13:1989. PubMed
  236. Saber M, et al. 2021. J Neurotrauma. 38:2862. PubMed
  237. Wang Y, et al. 2022. Nat Cell Biol. 24:230. PubMed
  238. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
  239. Deets KA, et al. 2021. Elife. 10:. PubMed
  240. Murray CW, et al. 2022. Nat Commun. 13:1090. PubMed
  241. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  242. Zhong J, et al. 2021. Commun Biol. 4:865. PubMed
  243. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  244. Kabir AU, et al. 2018. JCI Insight. 3. PubMed
  245. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  246. Bravo JI, et al. 2021. STAR Protocols. 2(2):100406. PubMed
  247. Chng S, et al. 2016. Sci Rep. 6: 23820. PubMed
RRID
AB_312976 (BioLegend Cat. No. 103111)
AB_312977 (BioLegend Cat. No. 103112)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV™ 395 anti-mouse CD45 30-F11 FC
Go To Top Version: 2    Revision Date: 05.14.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account